First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company

December 18, 2023

https://www.globenewswire.com/news-release/2023/12/18/2797607/0/en/First-Wave-BioPharma-Announces-Entry-into-Term-Sheet-for-Business-Combination-with-ImmunogenX-Establishing-a-Leading-Late-Stage-GI-Focused-Biopharmaceutical-Company.html

Phase 3-ready latiglutenase, a targeted oral biotherapeutic for celiac disease, will expand First Wave BioPharma’s late-stage gastrointestinal (GI) disease clinical pipeline

Read more at globenewswire.com

Related news for (FWBI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.